Fulgent Genetics (NASDAQ:FLGT) Sets New 1-Year Low - Should You Sell?

Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report) reached a new 52-week low during trading on Tuesday . The stock traded as low as $15.99 and last traded at $16.36, with a volume of 150186 shares. The stock had previously closed at $16.16.

Analysts Set New Price Targets

Several research analysts have recently commented on FLGT shares. Piper Sandler reduced their price target on Fulgent Genetics from $26.00 to $22.00 and set a "neutral" rating on the stock in a report on Monday, November 11th. StockNews.com lowered Fulgent Genetics from a "hold" rating to a "sell" rating in a report on Wednesday, November 27th.

Fulgent Genetics Trading Up 0.2 %

The stock has a market capitalization of $516.97 million, a PE ratio of -3.06 and a beta of 1.39. The firm's fifty day moving average is $17.94 and its 200-day moving average is $19.99.

Insider Activity at Fulgent Genetics

In other Fulgent Genetics news, CEO Ming Hsieh sold 2,227 shares of Fulgent Genetics stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $18.26, for a total value of $40,665.02. Following the completion of the transaction, the chief executive officer now directly owns 703,711 shares of the company's stock, valued at $12,849,762.86. The trade was a 0.32 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders have sold 3,413 shares of company stock worth $62,321. Company insiders own 31.76% of the company's stock.

Hedge Funds Weigh In On Fulgent Genetics

Institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC grew its position in shares of Fulgent Genetics by 45.5% during the fourth quarter. GAMMA Investing LLC now owns 2,133 shares of the company's stock worth $39,000 after buying an additional 667 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in Fulgent Genetics by 5.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 35,324 shares of the company's stock valued at $652,000 after purchasing an additional 1,689 shares during the last quarter. Centiva Capital LP increased its stake in Fulgent Genetics by 16.5% in the third quarter. Centiva Capital LP now owns 12,538 shares of the company's stock valued at $272,000 after purchasing an additional 1,774 shares during the last quarter. Federated Hermes Inc. increased its stake in Fulgent Genetics by 4.4% in the fourth quarter. Federated Hermes Inc. now owns 41,882 shares of the company's stock valued at $774,000 after purchasing an additional 1,774 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in Fulgent Genetics by 267.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,693 shares of the company's stock valued at $50,000 after purchasing an additional 1,960 shares during the last quarter. 48.06% of the stock is owned by institutional investors and hedge funds.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.